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AbstrACt
Objective To determine levels of public registration for 
a cohort of clinical trials reviewed and given a favourable 
opinion by research ethics committees in the United 
Kingdom.
study design Audit of records.
setting Clinical trials receiving a favourable ethics opinion 
between 1 January 2016 and 30 June 2016.
Main outcome measures Correlation between trials 
on the UK research ethics committee database and any 
primary registry entry on the WHO International Clinical 
Trials Registry Platform or  clinicaltrials. gov as of 29 
August 2017 (14 to 20 months after the favourable ethics 
committee opinion).
results Over the study period 1014 trials received a 
favourable ethics opinion, with 397 (39%) registered 
on the European Union Drug Regulating Authorities 
Clinical Trials database, and 18 with an agreed clinical 
trial registration deferral. Excluding these trials, the total 
number subsequently requiring registration was 599, and 
of these 405 (40% of total) were found to be registered. 
Follow-up with the 194 investigators or sponsors of trials 
not found to be registered produced 121 responses with 
a further 10 (1%) trials having already registered, 55 
commitments to register and a variety of other responses. 
The overall registration rate was therefore 80%.
Conclusions Despite researchers and sponsors being 
reminded that registration of clinical trials is a condition of 
the research ethics committee (REC) favourable opinion, 
one-fifth of clinical trials either had not been registered, 
or their registration could not easily be found, 14 to 20 
months after receiving the favourable opinion letter. The 
methodology trialled here proved effective, and although 
there are positive indications of a culture change towards 
greater registration, our results show that more still needs 
to be done to increase trial registration.
IntrOduCtIOn  
As of 30 September 2013, it has been a UK 
policy condition of a favourable research 
ethics committee (REC) opinion that all clin-
ical trials are registered on a publicly acces-
sible database (see box 1 for the wording 
from the favourable opinion letter provided 
to researchers).1 This should ideally occur 
before the first participant is recruited in 
accordance with the Declaration of Helsinki,2 
or no later than 6 weeks after recruitment 
of the first participant. The requirement 
was a response to calls by groups such as 
the Cochrane Collaboration,3 the AllTrials 
campaign4 and the WHO5 who have argued 
convincingly for transparency around clinical 
trials in order to ensure that valuable research 
is not lost, and also to prevent unscrupulous 
researchers or investors hiding clinically or 
scientifically relevant results for commercial 
reasons.6 Trial registration has been required 
for certain types of trials since 2004 by the 
European Union (EU)7 and since 2007 by 
the USFood and Drug Administration,8 but 
in the latter case the full policy is not being 
enforced9 even though overall more trials are 
being registered.10 Non-regulatory attempts 
are being made by organisations such as the 
International Committee of Medical Journal 
Editors (ICMJE) who are making registra-
tion a requirement for publication,11 but 
national regulatory environments also seem 
to be important.12 13 Box 1 provides an extract 
of the trial registration wording from the 
research ethics committee’s (REC) favour-
able opinion letter that all researchers receive 
when a clinical trial is approved in the UK.
strengths and limitations of this study
 ► Registration of clinical trials on publicly accessible 
research registries is a matter of good research 
ethics. If clinical trials are not registered, research 
organisations can hide results or trials that they do 
not like.
 ► Since 2013 UK policy has required registration of all 
clinical trials as a condition of research ethics com-
mittee’s (REC) favourable opinion.
 ► By comparing the REC records with publicly ac-
cessible research registries, we have been able to 
accurately determine clinical trial registration rates.
 ► By comparing records held by a regulator with pub-
licly accessible registries we have for the first time 
produced a ‘true’ trial registration rate for the UK.
 ► A limitation comes from the use of only a subset of 
records rather than the whole REC database.
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Applications to National Health Service (NHS) RECs 
are made using the online Integrated Research Appli-
cation System (IRAS),14 which includes a filter question 
(see box 2) asking researchers to define the type of study 
or trial. In addition to the UK policy requirement for 
trial registration, there is a legal obligation for registra-
tion placed on Clinical Trials of Investigational Medicinal 
Products (CTIMPs) under the current European and UK 
clinical trials legislation.1 All trials with a Clinical Trials 
Authorisation (CTA) have an entry on the European 
Union Drug Regulating Authorities Clinical Trials data-
base (EudraCT), which is used to populate the publicly 
accessible EU Clinical Trial Register. However, the EU 
legislation has a specific registration exemption for phase 
I trials involving healthy volunteers,15 while other types 
of clinical trials are also not covered by the legal require-
ment to register. In order to determine compliance with 
its registration policy for these other types of trials, the 
Health Research Authority (HRA) conducted an audit 
in early 2016 looking specifically at phase I, device and 
‘other’ trial registration (N.B. although most of the HRA’s 
functions apply to research undertaken in England, the 
HRA also works closely with the other countries in the 
UK (Scotland, Wales and Northern Ireland) to provide 
a UK-wide system including a research ethics service, 
so was able to audit UK-wide records). The results were 
published on the HRA website in response to questions 
raised by a UK government inquiry into research integ-
rity.1 The audit authors concluded that more was needed 
to be done to highlight the registration requirements to 
sponsors, with subsequent HRA efforts centred around 
improved training events and updating the wording on 
the application form. This paper now describes a second, 
more systematic attempt to determine registration rates 
for phase I, medical devices and ‘other’ clinical trials 
receiving a favourable opinion from RECs 3 years after 
the registration requirement came into force.
MethOds
Inclusion criteria
This study included all applications to UK RECs during 
the period 1 January 2016 to 30 June 2016 where the 
investigator or research team had selected one of the 
first four options in the IRAS (Integrated Research Appli-
cation System) filter question 2 (defining the work as a 
clinical trial), and the trials had then ultimately received 
a favourable opinion from a UK REC. Studies with a 
legal requirement for a public registration on EudraCT 
(mainly phases II, III and IV CTIMPs) were marked as 
already registered.
extracting data from the hrA Assessment review Portal
A management information report was extracted from 
the HRA Assessment Review Portal (HARP) database16 
to identify trials within the scope of the study. There 
are specific data fields on HARP recording the research 
reference numbers including registration number for 
trials registered on EudraCT,  clinicaltrials. gov and/or 
the International Standard Randomised Controlled Trial 
Number Registry (ISRCTN), as well as an ‘other reference 
numbers’ field. This information is populated on HARP 
either through direct import from the IRAS application 
(data collected via question A5-1 of application prepared 
in IRAS) or as manual input by the REC Manager when 
they are advised of registration.
Initial trial registration searches
For trials without a registration number logged on HARP, 
a registration search was conducted in August 2017 using 
the full trial title, and if the trial could not be located 
with this, the short title and REC Reference number. The 
manual searches via the Google search engine sought to 
box 1 extract from the Favourable Opinion letter received 
by all investigators
registration of Clinical trials
All clinical trials (defined as the first four categories on the IRAS filter 
page) must be registered on a publicly accessible database. This should 
be before the first participant is recruited but no later than 6 weeks after 
recruitment of the first participant.
There is no requirement to separately notify the REC but you should do 
so at the earliest opportunity for example, when submitting an amend-
ment. We will audit the registration details as part of the annual prog-
ress reporting process.
To ensure transparency in research, we strongly recommend that all 
research is registered but for non-clinical trials this is not currently 
mandatory.
If a sponsor wishes to request a deferral for study registration within 
the required timeframe, they should contact  hra. studyregistration@ nhs. 
net. The expectation is that all clinical trials will be registered, however, 
in exceptional circumstances non-registration may be permissible with 
prior agreement from the HRA. Guidance on where to register is provid-
ed on the HRA website.
box 2 Filter question 2 of the Integrated research 
Application system (IrAs) form
2. Select one category from the list below: 
 ► Clinical trial of an investigational medicinal product 
 ► Clinical investigation or other study of a medical device 
 ► Combined trial of an investigational medicinal product and an inves-
tigational medical device 
 ► Other clinical trial to study a novel intervention or randomised clini-
cal trial to compare interventions in clinical practice 
 ► Basic science study involving procedures with human participants 
 ► Study administering questionnaires/interviews for quantitative anal-
ysis, or using mixed quantitative/qualitative methodology 
 ► Study involving qualitative methods only 
 ► Study limited to working with human tissue samples (or other hu-
man biological samples) and data (specific project only) 
 ► Study limited to working with data (specific project only) 
 ► Research tissue bank
 ►  Research database
If your work does not fit any of these categories, select the option below: 
 ► Other study
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locate the clinical trial on a publicly accessible registry. 
For the purposes of this search the standard applied was 
registration in any primary registry on the WHO Interna-
tional Clinical Trials Registry Platform,17 or  clinicaltrials. 
gov (this is not a primary WHO registry but is an Interna-
tional Committee of Medical Journal Editors acceptable 
registry).18 If the trial was located, the registration details 
(name of registry and registration number) were logged 
and HARP updated (for future reference if required).
Follow-up for trials not found
If a registry entry could not be located using either the 
HARP record or manual searches then the Chief Investi-
gator and Sponsor were contacted via email (for phase I 
trials the Chief Investigator only was contacted) and asked 
to provide registration details or a reason for registration 
having not taken place. Only a single email was sent with 
no reminders. Responses obtained over the following 
couple of weeks were recorded and HARP was updated 
where registration information was provided. Responses 
were reviewed and categorised to determine broad 
themes. If an email exchange was held with the applicant 
the response category was updated to reflect the final 
response (eg, if an applicant initially thought there was 
no requirement to register their trial but then did agree 
to register after receiving further guidance from the HRA 
then the trial was recorded as ‘will register’).
Patient and public involvement
The need for the audit described here was discussed 
at the HRA’s partner ‘Transparency Forum’ whose aim 
is to promote research transparency and understand 
opportunities, obstacles and levers.19 Preliminary results 
were made available on the HRA website in response to 
questions from the UK House of Commons Science and 
Technology Select Committee.20
results
data mining
A total of 1014 trials were initially identified using HARP, 
of which 397 were CTIMPs (phases II, III and IV) already 
registered through EudraCT. Of the remaining 617 trials, 
18 were trials with an agreed registration deferral. This 
deferral is allowed by the HRA in instances where public 
details of a mainly phase I but occasionally device trial 
might be considered commercially confidential, although 
there is still the expectation that the trial will be registered 
on a publicly accessible registry when the reason for the 
deferral is no longer valid, or immediately should the trial 
be terminated early for safety reasons. After these exclu-
sions, 599 trials remained. Registration records could be 
found on either HARP or through the manual search 
for 405 trials, leaving 194 unregistered trials (in addition 
to the 18 with deferrals). Data is summarised in figure 1, 
tables 1 and 2.
Eighty-four phase I trials were identified of which 17 
had an agreed clinical trial registration deferral. Of the 
registered phase I trials (n=58), most were registered on 
clinicaltrials. gov and only one in the ISRCTN registry. 
Eight trials were identified as being registered through 
the HARP data export and a further 50 were identified 
through manual searches.
Figure 1 Summary of search results: (A) Research applications receiving a final favourable opinion between 1 January and 30 
June 2016, falling into the first four categories of IRAS filter question 2. (B) Total number of trials registered (812) vs unregistered 
(202 including 18 with valid deferrals).
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A total of 206 device trials were identified with one 
having an agreed clinical trial registration deferral in 
place. Of the device trials registered (n=138), the majority 
were again registered on  clinicaltrials. gov with 10% on 
the ISRCTN registry. One trial was registered on the EU 
Clinical Trials Register (this is unusual for a device trial). 
Fifty-nine registrations were identified through the HARP 
data export and an additional 79 were located through 
manual searches.
A total of 327 ‘other’ clinical trials were included. This 
category includes surgery, radiotherapy, imaging investi-
gations, mental health investigations or therapies, phys-
iological investigations, trials of products not defined 
as medicines or medical devices (eg, nutritional) and 
complementary or alternative therapies.21 None of these 
had a registration deferral in place. Of those registered 
(n=209) just over 50% were on  clinicaltrials. gov, and just 
under half (46%) were on the ISRCTN registry. A small 
proportion of this trial type (1.4%) were registered on 
The Australian New Zealand Clinical Trials Registry, and 
the German Clinical Trials Register. Forty-three registra-
tions were found through the HARP data export and a 
further 166 through manual searches.
Investigator follow-up
A total of 194 follow-up emails were sent to the Chief 
Investigators/Sponsors for trials where we could not find 
registration details forto request confirmation of whether 
the trial has been registered and if not, what the reason 
for this was. One hundred and twenty-one responses were 
received and categorised (table 3). Some respondents 
queried the requirement to register so a reply was sent 
to clarify the UK policy position on trial registration, and 
a number of further responses were received. The email 
responses identified a further 10 trial that had been regis-
tered giving a final total of 812 with a valid registration 
(80%) out of the total 1014 trials in the cohort.
Nine Chief Investigators of phase I trials were contacted 
to request confirmation of whether the trial has been 
registered and if not, what the reason for this was. 
Five responses were received. Of these, two trials were 
reported to be registered but were not identified through 
the initial search (this is likely due to variations in the trial 
title on HARP or the registry), two trials were reported to 
have not proceeded and one trial reported to have regis-
tered through the EudraCT database and the results been 
Table 1 Number of included clinical trials by study type
Phase I Devices Others Total
Trials with a 
favourable opinion
84 206 327 617
Trials with HRA 
agreed deferral
17 1 0 18
Total number of 
trials known to be 
registered prior 
to contacting 
researchers
58 138 209 405
Total number of 
trials NOT known 
to be registered 
prior to contacting 
researchers
9 67 118 194
HRA, Health Research Authority. 
Table 2 Location of registration for phase I, Devices and Other trials, and how the registrations were found. Figures in 
parenthesis are percentages rounded to the nearest whole number
Phase I Devices Other Total
Number of eligible trials (excluding 18 trials with 
deferral)
67 205 327 599
Registration details found on HRA database (total) 8 59 43 110
  ISRCTN 0 1 17 18
  clinicaltrials.gov 8 57 25 90
  Other* 0 1 1 2
Registration details found after manual search 
(total)
50 79 166 295
  ISRCTN 1 13 79 93
  clinicaltrials.gov 49 66 85 200
  Other* 0 0 2 2
Total found to be registered 58 (87%) 138 (67%) 209 (64%) 405 (68%)
  ISRCTN 1 (2%) 14 (10%) 96 (46%) 111 (27%)
clinicaltrials.gov 57 (98%) 123 (89%) 110 (53%) 290 (72%)
  Other* 0 (0%) 1 (1%) 3 (1%) 4 (1%)
*The Australian New Zealand Clinical Trials Registry (ANZCTR), EU Clinical Trials Register and German Clinical Trials Register (GermanCTR).
HRA, Health Research Authority; ISRCTN, International Standard Randomised Controlled Trial Number Registry.
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posted there. This respondent also referenced the trial 
details being publicly available on the HRA website.
Sixty-seven Chief Investigators and Sponsors were 
contacted for device trials after their trial could not be 
located on a registry. Forty-one responses were received. 
Nearly 20% responded to say that they would register the 
trial, most commonly specifying  clinicaltrials. gov or the 
ISRCTN Registry. Twelve per cent of respondents (n=5) 
advised that they had registered and were awaiting the 
registration number. 12% of respondents also stated that 
their trial was registered (despite not being found on 
HARP or through our initial manual search) and provided 
valid registration details. Three of these were registered 
on the ‘Research Registry’. Although this registry is not a 
primary registry in the WHO registry network it is listed 
on the research transparency page of the HRA website as 
a useful link under research registries. Two respondents 
reported to have registered on the NIHR portfolio and 
another respondent advised that their trial was not yet 
registered but ‘intended to follow normal guidance from 
NIHR about public accessibility’. At least seven respon-
dents initially claimed that their trial was not a clinical trial 
(eg, their response stated that the trial was an observation 
or feasibility trial and therefore they did not consider it 
as a clinical trial). One respondent noted that their local 
R&D team advised that registration was not necessary as 
the trial was not a clinical trial. Of the respondents that 
initially claimed their trial was not a clinical trial, only two 
respondents did not send a further email to confirm that 
they would register the trial. Four respondents replied 
with names of websites/databases as to where their trial 
was registered (box 3).
One hundred and eighteen Chief Investigators and 
Sponsors of ‘other’ clinical trials were contacted after 
their trial could not be found on a registry. Seventy-five 
responses were received. Over one-third of replies advised 
that they would register the trial. One respondent advised 
that they would ‘review their sponsorship processes to ensure 
that a check on clinical trial registration is built into our spon-
sorship workflows’. Five respondents reported to have regis-
tered on the NIHR Clinical Research Network Portfolio. 
Six respondents replied with names of websites/data-
bases as to where their trial was registered (box 3). Three 
respondents advised that their trial was already registered 
(these were not found through the initial manual search) 
and provided registration details. Two of these were on 
box 3 Alternative databases or registries named by 
correspondents
 ► Aberystwyth University’s online research repository/database, 
CADAIR.
 ► Clinical research network portfolio of stroke projects.
 ► HRA Research Summaries website (http://www. hra. nhs. uk/ news/ 
research- summaries/).
 ► University of Sheffield post-graduate research database (https://
www. sheffield. ac. uk/ medicine/ prospectivepg/ taught/ mmedsci/ 
currentresearch).
 ► Scottish Pulmonary Vascular Unit (www. spvu. co. uk).
 ► Open science framework website (https:// osf. io/ sd4yh/) (log in de-
tails required).
 ► Public Health Wales Research and Development Activity webpage.
 ► The Health Foundation (www. health. org. uk).
 ► Various Trusts/intranet R&D pages.
Table 3 Summary of responses to follow-up emails requesting confirmation of trial registration
Phase I Devices Other Total
Number contacted by email 9 67 118 194
No response (percentage) 4 (44%) 26 (39%) 43 (36%) 73 (38%)
Response 5 (56%) 41 (61%) 75 (64%) 121 (62%)
  Will register 0 8 26 34
  Study did not proceed* 2 6 7 15
  Registered (awaiting reference number) 0 5 6 11
  Applicant claimed not a clinical trial 0 2 8 10
  Now registered (following email) 0 3 7 10
  Already registered (not found in initial search) 2 5 3 10
  Registered on other database or website† 1 4 6 11
  Study not started 0 4 5 9
  Registered on the National Institute for 
Health Research (NIHR) portfolio
0 2 5 7
  On annual leave – will deal with on return 
(but no subsequent response)
0 1 2 3
  Stated in question A50 would not register 0 1 0 1
*Includes trials that were terminated or suspended.
†Two responses referred to the Health Research Authority research summary webpage as being classed as registered (one of these was a 
phase I study). Three responses provided links to a webpage, which included the study title only. 
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the ISRCTN Registry and two on the Research Registry. At 
least 20 respondents initially claimed that their trial was 
not a clinical trial. Examples of trial types where the appli-
cant claimed their trial was not a clinical trial included 
single case design student projects, a feasibility study, a 
small single arm observational and qualitative interview 
study. A number of respondents advised that the trial 
was a pilot with small sample size and did not regard it 
necessary to register the trial. One respondent reported 
that they decided not to register after discussions at the 
REC meeting. A small proportion of responses claimed 
they had inadvertently selected the incorrect study type 
on the IRAS application form. One response stated that 
they selected ‘Other CT’ as it was the least inappropriate 
category on the IRAS filter page. One respondent who 
claimed that their study was not a clinical trial advised that 
they had ‘received confirmation from the MHRA (UK Medi-
cines and Healthcare Products Regulatory Agency) that it 
is not a CTIMP and does not require a CTA.’ Two respondents 
questioned whether it was worthwhile registering retro-
spectively, with one individual noting ‘This would seem to 
defeat the purpose of pre-registration.’ Of the respondents who 
initially claimed their study was not a clinical trial, over 
half of respondents subsequently confirmed that they 
would register the trial or had since registered. A number 
of respondents asked for additional guidance on how to 
register and which registries were appropriate for their 
trial type. Some respondents were under the impression 
that the HRA Research Summary webpage was a form of 
trial registration. For example one respondent queried, 
‘If we register this study on www. clinicaltrials. gov then do we 
need to register this on HRA website too?’
Comparison to previous hrA audit
Compared with the HRA’s initial registration audit in 
early 2016, we found phase I registration rates up from 
63% to 87%, medical device trials up from 48% to 67% 
and ‘other’ trials up from 48% to 64%. Following identi-
fying the further 10 registered trials through our email 
contact with the investigators (not found in our manual 
search due to discrepancies in study titles and errors in 
reference numbers), the final registration rates were 90% 
for phase I, 70% for medical devices and 65% for ‘other’. 
These figures represent the registration rate at the time 
of this study being started and do not include subsequent 
registrations that occurred after the sponsors and investi-
gators had been reminded by email. The previous HRA 
audit found registrations increased up to 77% (phase I), 
85% (devices) and 80% (other) after email follow-up, 
while the approximately equivalent statistics from our 
study were 91%, 77% and 87% (figure 2).
dIsCussIOn
Including the 397 trials registered through EudraCT 
the overall registration rate for the studies included in 
our search criteria was 80%. For the purpose of calcu-
lating this percentage we decided to classify both the 18 
studies with valid deferrals and the nine that had not yet 
started as ‘not registered’ (although we acknowledge that 
these 27 studies have no policy requirement for registra-
tion). This 80% figure is broadly consistent with other 
studies,12 22 but is the first time this has been calculated 
for studies having been reviewed by RECs in the UK. 
This is significant because clinical trials conducted in the 
UK fall under legislation or policy requiring them to be 
reviewed by RECs and, as a result the REC records contain 
the only complete record of all clinical trials. Previously 
it has been very difficult for researchers and systematic 
reviewers to discover whether trials have even occurred 
as often the only public record is the registry itself. By 
auditing confidential data held by a regulator, and then 
comparing it with the public registry entries, the numbers 
reported here represent the first ‘true’ registration rate 
(certainly at a national level).
The increase in registration rates compared with the 
2016 HRA audit is encouraging as they show there is 
an upward trend in registration for all types of clinical 
trials examined here, suggesting a possible cultural shift 
within the trialist community. For instance, it is likely that 
the phase I registrations are higher because of aware-
ness among industry sponsors of the legal obligation to 
publicly register phases II, III and IV clinical trials, and 
thus the inclusion of public trial registration as a stan-
dard function of contract research organisations tasked 
with overseeing the governance aspects of trial prepara-
tion. Likewise a number of phone calls were made to the 
HRA following the email contact in the previous audit to 
query what was being asked, whereas none were reported 
during the course of this study. It is interesting to note 
that the phase I registrations and ‘other’ registration rates 
were higher compared with the first audit, but the device 
registrations were down slightly. While it is encouraging 
that more registrations occur following a simple email 
Figure 2 Change in registration rates between initial 
2016 Health Research Authority (HRA) audit and this audit, 
illustrating registration rates before and after email contact 
with researchers. Orange: 2016 HRA audit no email contact; 
Green: 2016 HRA audit following email contact; Blue: this 
study prior to email contact; Red: this study following email 
contact.
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contact, the ambition is not to have to follow-up in this 
way.
The response rate from investigators and sponsors was 
also encouraging especially as most responses were received 
within a week. Overall the responses and reasons given 
for not registering were in line with other studies.13 It was 
concerning that 20 of the 194 emails sent were undeliv-
erable, indicating out of date contact information in the 
HARP database. A number of respondents also claimed that 
they had picked the wrong box on the application form, 
again showing that the information contained within HARP 
is not always accurate. Of the other respondents, 65 trials 
were either registered or committed to register soon after 
receiving our email, while another 18 thought they had regis-
tered (although these were not on the approved registries), 
making up 42% of the studies contacted by email. Unfortu-
nately no answer was received for 38% (73 trials) contacted 
by email and 8% (15 trials) thought that they no longer 
needed to register as the trial was not eventually conducted. 
While we agree that the ethical argument for registering a 
trial might not be as strong for trials that were never started, 
we do think that such trials should still be registered with a 
brief explanation as to why the trial was not conducted so as 
to avoid future researchers or systematic reviewers trying to 
track down trial results that never existed. However, of most 
concern was the study that stated it would not register; this 
is an issue that probably should have been discussed by the 
ethics committee when they originally reviewed the trial.
A wider issue of note concerns the 10 studies that inves-
tigators claimed were not clinical trials and therefore did 
not require registration. Although it is not currently a UK 
policy that studies not in the top four categories of the IRAS 
filter question two are registered, it is difficult to see how this 
can be justified ethically. While clinical trials and especially 
CTIMPs represent the most medically risky studies as far as 
participants are concerned, research money and effort can 
also be wasted by not adequately reporting the existence of 
other types of studies as well.23–25 This is an issue that needs 
further consideration, and here it is encouraging that organ-
isations such as the ‘Research Registry’26 exist that enable 
research of any type to be registered.27
The HARP database includes full copies of the REC 
application form filled out by the research team with 
two key questions regarding research registration. 
Question A5-1 asks for research reference numbers 
including ‘registry reference numbers’ and gives a 
variety of options and types of reference numbers 
along with the text:
The UK Policy Framework for Health and Social Care 
Research sets out the principle of making informa-
tion about research publicly available. Furthermore 
Article 19 of the World Medical Association 
Declaration of Helsinki adopted in 2008 states that 
‘every clinical trial must be registered on a publicly 
accessible database before recruitment of the first 
subject’; and the International Committee of Medical 
Journal Editors (ICMJE) will consider a clinical trial 
for publication only if it has been registered in an ap-
propriate registry
The same text is replicated many pages later in 
the ‘Publication and Dissemination’ section of the 
form where question A50 asks ‘Will the research be 
registered on a public database?” provides ‘yes’ and 
‘no’ boxes, and then asks for details especially if the 
‘no’ box is checked. Although the guidance notes 
do remind researchers to also add registry numbers 
in section A5-1, the replication in IRAS is perhaps 
unfortunate. RECs have been encouraged to pay 
special attention to these sections and explicitly ask 
researchers about registration, but given that these 
sections were empty or included a variety of ambig-
uous numbers including local reference numbers 
and insurance numbers, this may not be happening. 
Indeed the fact that a manual search needed to be 
used alongside the information contained within 
these sections for 295 studies demonstrate that this 
data field is not being appropriately populated within 
the HARP database.
Putting the full trial title, or often the abbreviated 
trial title, into the Google search engine proved surpris-
ingly effective for identifying registered studies, and 
there were only 10 cases where this did not work (and 
registration was subsequently confirmed by email). 
This is again a positive finding as it means that trial 
details can be found by non-expert searchers using a 
popular and accessible search engine. However, it is 
concerning that this search helped to identify 36% (295 
out of 802) of registered trials with incorrect or absent 
registration numbers in the HARP database. Although 
registration numbers may not legitimately be available 
at the time of REC review, it would be fairly trivial to 
update RECs either in the response letter to the REC 
review, or through a subsequent minor amendment. 
This is an area of improvement that could be looked 
at, perhaps by requiring an amendment once the regis-
tration is confirmed.
One limitation of this audit was only including clinical 
trials that had been approved in a 6 month time frame. 
This was based on a pragmatic attempt to limit the audit 
to about 1000 clinical trials in order to determine the 
practicality of the method and produce a baseline figure. 
If this audit is to be repeated on a regular basis more 
resources would be needed to deal with the couple of 
thousand clinical trials that are reviewed by UK RECs 
each year. The incompleteness of HARP records coupled 
with the presence of invalid email addresses also limited 
the information that could be obtained on each trial, 
but future work could attempt to determine alternative 
contacts within sponsoring organisations to obtain defini-
tive data on each and every trial. A further analysis of the 
unregistered trials could also be interesting as a way of 
determining whether there are any specific types of trials 
that are more likely not to register.
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COnClusIOns
The study reported here represents the first systematic 
attempt to compare records of clinical trials held by a 
national regulator with publicly accessible trial registries. 
Registration rates have improved from initial audit figures 
provided by the HRA (figure 2), and it is heartening to 
see more evidence of a cultural change within the trialist 
community towards greater registration.10 However, to 
date, the research ethics service has adopted the approach 
of encouraging greater trial registration through educa-
tion rather than sanctioning Chief Investigators or 
Sponsors who do not register trials. It is likely that this 
situation may soon change based on recommendations 
made by the UK House of Commons Science and Tech-
nology Select Committee (Commons) in their report on 
Clinical Trials Transparency published in October 2018.20 
The committee recommended that measures be put in 
place to ensure 100% of clinical trials get registered. It 
is difficult to see how this target can be achieved without 
a more complete audit modelled on the one described 
here, followed by organisations such as the HRA consid-
ering the use of sanctions with sponsors or investigators 
who are found not to have registered their studies.
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